Funded Biotechnology Startups in Atlanta
Atlanta's biotechnology funding activity in this dataset spans April 2021 through August 2024, with disclosed deal sizes ranging from TendoNova's $450K ven…
Atlanta's biotechnology funding activity in this dataset spans April 2021 through August 2024, with disclosed deal sizes ranging from TendoNova's $450K venture round (August 2022) to Vero Biotech's $100M Series E (December 2021). The two largest rounds — Vero Biotech at $100M and Antios Therapeutics at $96M Series B (April 2021) — both closed in 2021, while the most recent activity has been considerably smaller: Moonlight Therapeutics at $2M (August 2024) and Andson Biotech at $4M (March 2024).
Four companies — Moonlight Therapeutics, Hypercell Technologies, BioCircuit Technologies, and TendoNova — carry a "Series Unknown" classification, and Andson Biotech has no round type on record, leaving five of ten without a confirmed stage. The middle of the disclosed range includes Florence Healthcare's $27M Series C (June 2022) and Lucid Scientific's $7M Series A (September 2023). Clearwave, which closed a private equity round in October 2021, did not disclose its amount.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Atlanta biotech companies in this dataset?
Vero Biotech raised $100M in a Series E (December 2021) and Antios Therapeutics raised $96M in a Series B (April 2021) — both well above the rest of the group. Florence Healthcare's $27M Series C (June 2022) is the next largest disclosed amount.
Which companies have the most recent funding dates?
Moonlight Therapeutics closed a $2M round in August 2024, and Andson Biotech raised $4M in March 2024. Both have unconfirmed or missing round-type classifications, which limits stage visibility.
How many companies here lack a confirmed round stage?
Five of the ten. Moonlight Therapeutics, Hypercell Technologies, BioCircuit Technologies, and TendoNova are each listed as 'Series Unknown' or 'Venture - Series Unknown,' and Andson Biotech has no round type on record at all. This limits reliable stage-based segmentation without supplemental data.
Is there any late-stage or growth-stage activity in this group?
Vero Biotech's $100M Series E (December 2021) is the clearest late-stage marker. Clearwave received private equity funding in October 2021, though no amount was disclosed. Florence Healthcare's $27M Series C (June 2022) also places it at a later stage relative to the rest of the dataset.
Which companies raised under $5M, and when did those rounds close?
Five companies fall below the $5M threshold: TendoNova ($450K, August 2022), Hypercell Technologies ($1M, November 2023), Moonlight Therapeutics ($2M, August 2024), BioCircuit Technologies ($2M, October 2023), and Andson Biotech ($4M, March 2024). Four of these five closed in 2023 or 2024.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.